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Abstract: A model test-system was developed for validation in vitro of antihypoxic and 
endothelio-differentiating activity of newly created glycogen synthase kinase-3 inhibitors in 
comparison with the reference drug β4-thymosin. 
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Glycogen synthase kinase 3 (GSK-3) is a 
tyrosine kinase participating in many of the central 
cell signaling pathways, including proliferation, 
migration, and apoptosis. The process of protein 
phosphorylation with the involvement thereof 
normally inhibits the activity of subsequent elements 
in the signal transduction chain. GSK-3 activity 
inhibitors are promising candidates for the role of 
drugs used in many diseases, including the role of 
stimulators of tissue repair and neoangiogenesis, and 
inducers of myelopoiesis in different areas [1, 2].  
One of the challenges in the development of new 
drugs is a screening of biological activity of 
synthesized candidate molecules. Currently, most of 
the experimental and preclinical studies in Russia is 
carried out in laboratory animals, which, in our 
opinion, is not the best solution. It is difficult to 
detect and control all body-level chemical and 
biological processes occurring with a medicament, 
including strength of initially unknown 
pharmacokinetic characteristics of new chemical 
compounds, and inaccurate correspondence between 
the active substance in an animal and a human. There 
are also issues of the ethics of using living models, 
and the lack of model animals applicable for some 
conditions and diseases. In this regard, 
pharmacologists and pharmaceutical companies start 
using more actively the cell cultures in the early 
stages of development and testing of new drugs [3]. 
The described approach is free from dangerous 
shortcomings for animals, otherwise, a wide range of 
standardized and primary cell lines allows developing 
an adequate model virtually for any potential 
medicines and screening of biological activity of the 
synthesized candidate molecules. 
This paper deals with the development of a model 
cell test system for testing the biological activity of new 
GSK-3 inhibitors in the experiments in vitro. Any 
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model requires using certain control substance with 
known activity to conduct a comparative study of new 
molecules. For the GSK-3 inhibitors, we chose β4-
thymosin studied in sports pharmacology and in some 
other areas of medicine [4, 5, 6], and available in the 
form of ready substance.  
Materials and methods. 
Endothelial progenitors were obtained from bone 
marrow of 10 Wistar rats aged 3-4 weeks, sacrificed by 
decapitation under ether anesthesia, by the modified 
method by Nana Y. et al. [7]. Bone marrow was washed 
with phosphate-buffered saline (PBS, pH = 7.4; PanEco 
# R074) using a syringe out of the diaphysis and 
mechanically crushed epiphysis of tubular bones of 
limbs. For removal of bone, connective tissue and 
muscle fragments, the washed bone marrow was 
filtered through nylon filters (SPL LifeSciences 
#93100) with a pore diameter of 100 µm. 
The filtered cell suspension in PBS was 
carefully transferred to a ficoll-urografin solution 
with ρ=1.077 (PanEco #P052) and centrifuged at 
2000 rev/min for 20 min at room temperature. A 
ring-shaped mononuclear fraction on the ficoll-
urografin surface was carefully collected and 
transferred to new centrifuge tubes (SPL 
LifeSciences # 51115), re-suspended in PBS and 
centrifuged at 1500 rev/min for 10 minutes at room 
temperature. The supernatant was aspirated, and the 
settled cells were again re-suspended in PBS and 
centrifuged under the same conditions, after which 
the supernatant was removed. The cell pellet was re-
suspended in complete medium containing Medium 
199 (PanEco #S210p), 15% fetal bovine serum 
(HyClone#K052/SV30160.03), 10 ng/ml FGFb 
(PanEco #FR07010) and 20 ng/ml VEGF (Sigma 
#V4512), and dissipated on a 24-well plate (Corning 
Costar #3524) at the rate of 100 thousand cells per 
well. Further, incubated in a humidified atmosphere 
of 5% CO2 at 37°C. 
After 2 days, the cells not attached to the well 
bottom were removed and a new complete growth 
medium was added to the attached cells. Further, 
every 3 days, a half of the medium was removed and 
equal volume of fresh complete medium was added 
to each well. 
After 11 days, the supernatant was completely 
removed from cells and fresh complete medium was 
introduced to a portion of the cells – with the addition 
of β4-thymosin (LCN Bio-Chemicals Limited) at a 
concentration of 2 mg/ml. The cells were incubated 
for 3 days in a humidified atmosphere of 5% CO2 at 
37°C. Cell ischemia was simulated by blocking 
oxygen delivery to cells through the formation of an 
oil film on the surface of the culture medium in the 
plate wells, with the use of cell-indifferent mineral oil 
(Sigma #M5310). The duration of hypoxia was 2, 4, 
6 and 8 hours. In addition, some of the cells were 
subjected to further "starvation", by replacing the 
medium with the PBS. 
The total number of cells was assessed by 
counting the cell in 5 adjacent fields of view in each 
well of the plate by using Hoffman staining with 
Eclipse Ti-S (Nikon) fluorescence microscope. The 
number of viable cells was assessed by fluorescence 
microscopy using fluorochromes: calcein – AM 
(Sigma #17783) and ethidium bromide (Sigma 
#E7637) in the same fields of view. Belonging to the 
endothelial progenitors was evaluated by membrane 
expression of Flk1/VEGFR1 specific marker stained 
by double antibody (SantaCruz #sc-505 and #sc-
2012) fluorescence method. 
Results and discussion. 
Subject to the interest in the anti-ischemic and 
angiogenic effect of the GSK-3 inhibitors, we have 
studied the β4-thymosin ability to influence these 
parameters in our model. 
Upon assessing the dynamics of the total number 
of cells in the plate wells under hypoxia (Figure 1), 
we found a protective effect of β4-thymosin on cells, 
which persists throughout all hypoxia – even at 6 and 
8 h of hypoxia the test wells with a nutrient medium 
and β4-thymosin retained 22.9 ± 2.7 and 20.2 ± 2.0 
cells, respectively, in the 5 fields of vision 
(hereinafter, M±tm, n=10), while the number in the 
control continued to decrease progressively up to  
1.9 ± 1.2 and 0.9 ± 0.6 cells in these periods of time. 
The differences between the control and the β4-
thymosin-containing medium were significant 
(p<0.05). Under hypoxia and “starvation”, there was 
a sharp decline in the number of cells at the 
beginning of the experiment – from 54.4±2.6 to 
36.2±1.9 after 2 hours, and to 6.0±0.7 cells after 4 
hours, which exceeded the initial values, where the 
number of cells was decreasing slower – from 
30.1±1.3 to 20.0±1.0 after 2 hours, and to 11.8±1.0 
after 4 hours. 
The dynamics of cell death in the wells against 
their initial number is shown in Fig. 2. 
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Figure 1.The absolute number of cells in 5 fields of view 
 
 
 
 
Figure 2. The percentage dynamics of the number of cells in 5 fields of view 
 
According to these graphs, we cannot exclude a 
protective effect of β4-thymosin expressing at long 
stay of the cells under hypoxic and "starvation" 
conditions, because, despite the sharp decline in the 
number of cells in the early hours of combined 
ischemia, the wells with the PBS had more cells 
remained than the control wells at the later stages of 
the research (4.1±0.9 cells after 6 hours and 3.9±0.6 
cells after 8 h against 1.9±1.2 and 0.9±0.6 cells, 
respectively, – in the control). 
More pronounced protective effect of β4-
thymosin on cell survivability under hypoxia and 
combination of hypoxia with "starvation" is shown in 
Figures 3 and 4, where the number and percentage of 
living cells in control is much lower than in test 
samples. 
 
 
 
Figure 3.The absolute number of living cells in 5 fields of view 
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Figure 4.The percentage dynamics of the number of living cells in 5 fields of view. 
 
According to the literature it is known that β4-
thymosin prevents apoptosis of endothelial progenitor 
cells in culture [5]. This ability, apparently, explains 
a large proportion of living cells in the test samples 
as compared to the control. However, the study found 
that the initial number of cells in the wells with the 
cultivation conducted for 3 days in the presence of 
β4-thymosin is higher than in β4-thymosin-free wells 
(columns K in Fig. 1). The experiment does not give 
an answer, to what extent this phenomenon is due to 
the anti-apoptogenic effect of β4-thymosin and 
whether the latter is able to stimulate the cell 
proliferation, since these mechanisms have not been 
studied yet. There is information the literature about 
both stimulating and inhibiting effect of β4-thymosin 
on proliferative activity of the cells through the 
implementation of Wnt and insulin signaling 
pathways [1]. 
The next stage of the experiment was to study 
the endothelial differentiation of adhesion fraction of 
bone marrow mononuclear cells, wherefore we 
counted the number of cells that express a marker of 
endothelial progenitor cells – early progenitors of 
endothelial cells – Flk-1 (VEGFR), which is a 
receptor of vascular endothelial growth factor. 
Results in Table 1 show that the presence of β4-
thymosin not just increases the total number of cells, 
but also significantly increases the percentage of cells 
that express the said endothelial progenitor marker - 
50.6±4.7% Flk+ cells in the control, and 82.8±2.2% 
upon cultivation for 3 days with β4-thymosin. 
Table 1 
Expression of endothelial progenitor marker (Flk-1
+
) in the culture of bone marrow MSCs 
 
 
Without β4-thymosin With β4-thymosin 
Total cells (M±tm) 20.8±1.3 51.0±2.4
* 
Flk-1
+
 cells (M±tm) 10.5±1.1 42.2±2.1
* 
% Flk-1
+
 cells 50.6±4.7 82.8±2.2
* 
 
Note: * - p<0.05 
 
Along with cardioprotective properties of  
GSK-3β [8, 9] inhibitors, shown by other researchers, 
the ability to stimulate the differentiation of MSCs 
into endothelial ones makes it more promising to 
study them in terms of prevention and treatment of 
coronary heart disease and arterial occlusive diseases. 
Thus, the experimental findings are consistent with 
the results obtained by other researchers involved in the 
study of biological activity of GSK-3 inhibitors and, in 
particular, β-thymosin.  The latter may further serve as a 
reference agent in comparative studies. Therefore, the 
proposed experimental cell model can be successfully 
used in the preliminary testing of new chemical 
compounds in terms of their curative potential in 
ischemic disorders without the use of laboratory 
animals at the early stages of research. 
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